Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
Nicox’s Partner Secures Additional Approvals of VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% in Hong Kong and Argentina

January 16, 2020

View Press Release Corporate presentation Contact us
Previous